Anti-VEGF may hasten improvement in symptomatic retinal arterial macroaneurysms
Intravitreal bevacizumab injection may speed improvement in macular edema and hemorrhage due to retinal arterial macroaneurysms, according to a study.
The retrospective study included 23 eyes of 23 patients with symptomatic retinal arterial macroaneurysm; 11 eyes were treated with Avastin (bevacizumab, Genentech) and a control group comprised 12 untreated eyes.
Bevacizumab was injected at the first visit and subsequently on a monthly as-needed basis; treated eyes received a mean 1.42 injections.
LogMAR best corrected visual acuity and central macular thickness were evaluated at 1, 3 and 6 months after initiation of treatment and at the final visit; mean follow-up was 10.83 months.
BCVA and central macular thickness improved significantly and remained stable in both groups at final follow-up.
In the bevacizumab group, BCVA was significantly improved after 1 month, while in the control group, BCVA was significantly improved after 3 months.
By the end of follow-up, the between-group differences in BCVA and central macular thickness improvement were insignificant.